Arcus Biosciences, Inc.
RCUS
Positions held
Your positionsRCUS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Arcus Biosciences is positioned in a competitive biotechnology market with innovative therapies that could lead to significant breakthroughs in cancer treatment.
- In the latest quarter, revenue increased by 141% compared to the prior quarter, reaching $41 million.
- The operating margin improved to -234.1%, indicating a potential turnaround in operational efficiency.
- The company is currently facing challenges with a negative profit margin and high debt-to-equity ratio, which raises concerns about financial stability.
- In 2023, Arcus reported a revenue of only $117 million, with a net income loss of $307 million.
- The stock has a strong sell signal with a score of -23.00, indicating bearish market sentiment and unfavorable technical indicators.
Fundamentals
| Market cap | $3.00B | Enterprise value | $2.57B | Trailing P/E | — | Forward P/E | -7.30 |
| PEG | — | Price / book | 6.52 | Beta | 0.94 | Dividend yield | 0.00% |
| Revenue growth | -74.4% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -2.3% |
| Profit margin | 0.0% | ROE | -90.8% | ROA | -30.4% | Debt / equity | 0.51 |
| Current ratio | 3.82 | Free cash flow | -$270.62M | Analyst recommendation | strong_buy | Mean target | $39.91 |
| 52w high | $31.74 | 52w low | $14.26 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $41.0M | $17.0M | $33.0M | $26.0M | $160M | — |
| Op margin | -234.1% | -788.2% | -345.5% | -546.2% | -5.0% | — |
| Net income | -$91.0M | -$128M | -$106M | -$135M | $0.0M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$96.0M | -$134M | -$114M | -$142M | -$8.0M | — |
- Revenue +141% vs prior quarter ($41M vs $17M).
- Operating margin expanded to -234.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $247M | $258M | $117M | $112M | — |
| Op margin | -156.3% | -120.2% | -290.6% | -250.0% | — |
| Net income | -$353M | -$283M | -$307M | -$267M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$386M | -$310M | -$340M | -$280M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Is Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage?
2026-10-05 · How Investors Are Reacting To Arcus Biosciences (RCUS) Expansive New Casdatifan ARC-20 Kidney Cancer Data
2026-09-24 · Arcus Biosciences Announces New Employment Inducement Grants
2026-09-16 · TD Cowen Initiates Arcus Biosciences at Buy
2026-09-09 · Arcus Biosciences Announces New Employment Inducement Grants
2026-08-26 · Arcus Biosciences to Participate in Three Upcoming Investor Conferences
2026-08-13 · Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript
2026-08-11 · Arcus Biosciences Announces New Employment Inducement Grants
2026-08-10 · Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says
2026-08-10 · Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating
Price (daily)
Full chart · RSI · MACD · patterns